News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
717,000 Results
Type
Article (69472)
Company Profile (469)
Press Release (647040)
Multimedia
Podcasts (163)
Webinars (23)
Section
Business (182857)
Career Advice (3250)
Deals (32449)
Drug Delivery (132)
Drug Development (83542)
Employer Resources (180)
FDA (16169)
Job Trends (14575)
News (322113)
Policy (31321)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2965)
Academic (1)
Accelerated approval (33)
Adcomms (36)
Allergies (145)
Alliances (48993)
ALS (181)
Alzheimer's disease (1788)
Antibody-drug conjugate (ADC) (341)
Approvals (16366)
Artificial intelligence (557)
Autoimmune disease (168)
Automation (34)
Bankruptcy (316)
Best Places to Work (11573)
BIOSECURE Act (19)
Biosimilars (191)
Biotechnology (322)
Bladder cancer (160)
Brain cancer (63)
Breast cancer (667)
Cancer (4985)
Cardiovascular disease (434)
Career advice (2767)
Career pathing (40)
CAR-T (309)
CDC (53)
Celiac Disease (2)
Cell therapy (833)
Cervical cancer (35)
Clinical research (70536)
Collaboration (1819)
Company closure (5)
Compensation (1104)
Complete response letters (69)
COVID-19 (2854)
CRISPR (99)
C-suite (853)
Cystic fibrosis (155)
Data (6313)
Decentralized trials (2)
Denatured (51)
Depression (149)
Diabetes (518)
Diagnostics (6575)
Digital health (45)
Diversity (11)
Diversity, equity & inclusion (44)
Drug discovery (274)
Drug pricing (200)
Drug shortages (32)
Duchenne muscular dystrophy (244)
Earnings (71376)
Editorial (65)
Employer branding (23)
Employer resources (160)
Events (116678)
Executive appointments (977)
FDA (19298)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1534)
Gene editing (216)
Generative AI (53)
Gene therapy (679)
GLP-1 (1065)
Government (4922)
Grass and pollen (7)
Guidances (369)
Healthcare (19295)
HIV (60)
Huntington's disease (48)
IgA nephropathy (86)
Immunology and inflammation (280)
Immuno-oncology (62)
Indications (104)
Infectious disease (3123)
Inflammatory bowel disease (203)
Inflation Reduction Act (16)
Influenza (113)
Intellectual property (250)
Interviews (631)
IPO (15544)
IRA (57)
Job creations (3378)
Job search strategy (2246)
JPM (68)
Kidney cancer (14)
Labor market (82)
Layoffs (590)
Leadership (39)
Legal (6734)
Liver cancer (91)
Longevity (15)
Lung cancer (669)
Lymphoma (379)
Machine learning (43)
Management (63)
Manufacturing (820)
MASH (174)
Medical device (13020)
Medtech (13071)
Mergers & acquisitions (18003)
Metabolic disorders (1356)
Multiple sclerosis (170)
NASH (21)
Neurodegenerative disease (350)
Neuropsychiatric disorders (99)
Neuroscience (3106)
Neurotech (1)
NextGen: Class of 2026 (6758)
Non-profit (4926)
Now hiring (62)
Obesity (649)
Opinion (330)
Ovarian cancer (167)
Pain (216)
Pancreatic cancer (227)
Parkinson's disease (296)
Partnered (35)
Patents (497)
Patient recruitment (489)
Peanut (60)
People (55848)
Pharmaceutical (84)
Pharmacy benefit managers (31)
Phase 1 (22148)
Phase 2 (30983)
Phase 3 (23047)
Pipeline (5199)
Policy (320)
Postmarket research (2768)
Preclinical (9913)
Press Release (71)
Prostate cancer (249)
Psychedelics (56)
Radiopharmaceuticals (299)
Rare diseases (925)
Real estate (5880)
Recruiting (76)
Regulatory (24226)
Reports (42)
Research institute (2700)
Resumes & cover letters (512)
Rett syndrome (28)
RNA editing (21)
RSV (76)
Schizophrenia (157)
Series A (261)
Series B (195)
Service/supplier (15)
Sickle cell disease (104)
Special edition (27)
Spinal muscular atrophy (172)
Sponsored (48)
Startups (3563)
State (2)
Stomach cancer (19)
Supply chain (105)
Tariffs (85)
The Weekly (111)
Vaccines (1058)
Venture capital (94)
Weight loss (435)
Women's health (82)
Worklife (22)
Date
Today (99)
Last 7 days (587)
Last 30 days (2101)
Last 365 days (30834)
2026 (3015)
2025 (31190)
2024 (35989)
2023 (40543)
2022 (51659)
2021 (56061)
2020 (54162)
2019 (47125)
2018 (35691)
2017 (33049)
2016 (32921)
2015 (38206)
2014 (30820)
2013 (26686)
2012 (27572)
2011 (27998)
2010 (26311)
Location
Africa (1004)
Alabama (91)
Alaska (7)
Arizona (254)
Arkansas (14)
Asia (42587)
Australia (7672)
California (11192)
Canada (3229)
China (1160)
Colorado (468)
Connecticut (476)
Delaware (331)
Europe (99385)
Florida (1651)
Georgia (356)
Hawaii (3)
Idaho (63)
Illinois (875)
India (67)
Indiana (492)
Iowa (24)
Japan (430)
Kansas (130)
Kentucky (38)
Louisiana (27)
Maine (60)
Maryland (1361)
Massachusetts (8315)
Michigan (322)
Minnesota (625)
Mississippi (4)
Missouri (130)
Montana (32)
Nebraska (25)
Nevada (113)
New Hampshire (78)
New Jersey (3004)
New Mexico (32)
New York (2968)
North Carolina (1494)
North Dakota (9)
Northern California (5424)
Ohio (338)
Oklahoma (21)
Oregon (41)
Pennsylvania (2251)
Puerto Rico (19)
Rhode Island (46)
South America (1298)
South Carolina (64)
South Dakota (1)
Southern California (4350)
Tennessee (147)
Texas (1711)
United States (39967)
Utah (316)
Vermont (1)
Virginia (264)
Washington D.C. (80)
Washington State (948)
West Virginia (4)
Wisconsin (110)
Wyoming (2)
717,000 Results for "the multiple myeloma research foundation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
FDA’s Multiple Myeloma Guidance Highlights Decade of Success
New draft guidance from the FDA on multiple myeloma endpoints reflects the new technology available to assess disease and how patient journeys have changed with better treatments.
January 30, 2026
·
4 min read
·
Dan Samorodnitsky
Cancer
J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication, Pushing Into Frontline
Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed patients with multiple myeloma, regardless of eligibility for stem cell transplantation.
January 28, 2026
·
2 min read
·
Tristan Manalac
Opinion
Counteracting Complacency in Multiple Myeloma—We’re Not There Yet
Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must continue.
October 20, 2025
·
6 min read
·
Michael Andreini
FDA
J&J Wins Proactive FDA National Priority Voucher for Multiple Myeloma Combo
Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a Phase III study testing Tecvayli plus Darzalex in patients with relapsed or refractory multiple myeloma.
December 16, 2025
·
2 min read
·
Tristan Manalac
Approvals
J&J Wins Expansion for Top-Selling Cancer Drug in First for Smoldering Multiple Myeloma
Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of progression to active disease.
November 7, 2025
·
2 min read
·
Tristan Manalac
Approvals
GSK’s Blenrep Makes Comeback With FDA Nod for Third-Line Multiple Myeloma
The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved Thursday by the FDA for previously treated patients with multiple myeloma. This is despite a negative advisory committee vote in July.
October 24, 2025
·
2 min read
·
Tristan Manalac
Press Releases
CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting
- Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients - - Observed response rates of 60-75% with inobrodib 20 mg and 30 mg cohorts result in clinical efficacy at least two-fold higher than previously published real-world data for pom-refractory, bispecific or anti-BCMA exposed patients -
December 9, 2025
·
4 min read
Press Releases
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
December 8, 2025
·
23 min read
Cancer
ASH25: Late-Stage Data For J&J’s Tecvayli/Darzalex Combo Could ‘Shift Paradigm’ in Myeloma
Tecvayli plus Darzalex led to an 83% boost to progression-free survival versus the current standard therapy in relapsed or refractory multiple myeloma, results analysts at Guggenheim Securities called “remarkable.”
November 25, 2025
·
2 min read
·
Tristan Manalac
Press Releases
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
January 28, 2026
·
24 min read
1 of 71,700
Next